A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs DS 1205 (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 26 Sep 2018 Retrospective analysis of AXL expression by immunohistochemistry will be conducted using tumor tissue collected prior to study treatment, as per trial design presented the 19th World Conference on Lung Cancer.
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.